Source link : https://www.newshealth.biz/health-news/abecma-approved-for-earlier-lines-in-r-r-multiple-myeloma/
The US Food and Drug Administration (FDA) has approved idecabtagene vicleucel (ide-cel) (Abecma, Bristol-Myers Squibb/2seventy bio) for adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. The approval expands the chimeric antigen receptor (CAR) T-cell therapy’s indications […]
Author : News Health
Publish date : 2024-04-08 18:02:32
Copyright for syndicated content belongs to the linked Source.
Categories